NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial

NeuroBo Pharmaceuticals (NRBO) has issued an update.

NeuroBo Pharmaceuticals, Inc. has successfully completed the enrollment for the first part of its Phase 1 clinical trial for DA-1726, a promising new drug aimed at treating obesity. The trial has included 45 participants across 5 cohorts to test the efficacy of the OXM analog agonist. The company issued a press release to announce this milestone, cautioning that the forward-looking statements are not guarantees of future results, and actual outcomes could vary. The press release is part of a regulatory filing that, while not constituting an official filing for securities law purposes, is necessary for corporate transparency.

See more insights into NRBO stock on TipRanks’ Stock Analysis page.